Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11614947 | 0.78 | PIK3CD (0.55) | CYP11B1CYP11B2PIK3CDALDH1A1MEN1 | |
| SCHEMBL29929823 | 0.78 | EGLN2 (0.42) | EGLN2CYP11B1CYP11B2PIK3CDALDH1A1 | |
| SCHEMBL186339 | 0.78 | EGLN2 (0.42) | EGLN2CYP11B1CYP11B2PIK3CDALDH1A1 | |
| SCHEMBL13889780 | 0.75 | PIK3CD (0.40) | CYP11B1CYP11B2PIK3CDALDH1A1MEN1 | |
| SCHEMBL480098 | 0.75 | PIK3CD (0.40) | EGLN2PIK3CDALDH1A1MEN1KMT2A | |
| SCHEMBL3183508 | 0.75 | HTT (0.46) | CYP11B1CYP11B2PIK3CDALDH1A1MEN1 | |
| SCHEMBL1303846 | 0.75 | ALDH1A1 (0.44) | EGLN2CYP11B2PIK3CDALDH1A1MEN1 | |
| SCHEMBL12721108 | 0.75 | EGLN2 (0.40) | EGLN2CYP11B1CYP11B2PIK3CDALDH1A1 | |
| SCHEMBL2298550 | 0.75 | EGLN2 (0.40) | EGLN2CYP11B1CYP11B2ALDH1A1KHK | |
| SCHEMBL1977038 | 0.75 | EGLN2 (0.40) | EGLN2CYP11B1CYP11B2PIK3CDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067483-A1 | AMIDE COMPOUNDS | 中国药科大学 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025045058-A1 | COMPOUND ACTING AS ANDROGEN RECEPTOR ANTAGONIST | 中国药科大学 | 2025-03-06 | — | — | WO | disclosed |
| US-20220411381-A1 | PYRIMIDINEDIONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | US | disclosed |
| EP-4038054-A1 | PYRIMIDINEDIONE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021063821-A1 | PYRIMIDINEDIONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-08 | — | — | WO | disclosed |
| EP-2934538-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3604326-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-10000488-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3192791-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-1854798-A2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | Bristol-Myers Squibb Company (US) | 2007-11-14 | — | — | EP | disclosed |
| US-7141578-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-28 | — | — | US | disclosed |
| US-20060264459-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-11-23 | — | — | US | disclosed |
| US-20060223832-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-10-05 | — | — | US | disclosed |
| EP-1458723-A4 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-08 | — | — | US | disclosed |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | EGLN2 607/4885CYP11B1 71/4885CYP11B2 96/4885 |
| US-20060223832-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | EGLN2 607/4885CYP11B1 71/4885CYP11B2 96/4885 |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | EGLN2 607/4885CYP11B1 71/4885CYP11B2 96/4885 |
| US-20060264459-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | EGLN2 607/4885CYP11B1 71/4885CYP11B2 96/4885 |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | EGLN2 607/4885CYP11B1 71/4885CYP11B2 96/4885 |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | EGLN2 2914/4885CYP11B1 47/4885CYP11B2 57/4885 |
| US-20220411381-A1 | PYRIMIDINEDIONE DERIVATIVES | DPYD, TYMP, TYMS | EGLN2 2701/4885CYP11B1 824/4885CYP11B2 1023/4885 |
| US-10000488-B2 | Heterocyclic compound | RORC, RORB, RORA | EGLN2 2914/4885CYP11B1 47/4885CYP11B2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.